Drug intelligence / Profile preview

polycan

Development stage
Preclinical
Lead developer
Glucan
Administration
Oral
01

Overview

Polycan is a water-soluble $\beta$-1,3/1,6-glucan complex of extracellular polysaccharides purified from the *Aureobasidium pullulans* strain SM-2001. Developed by Glucan Co., Ltd., it features a specific molecular structure with $\beta$-1,3 and $\beta$-1,6 linkages in a 68:32 ratio and an average molecular weight of approximately 260 kDa. Polycan acts as an immunomodulator and anti-inflammatory agent, demonstrating the ability to reduce levels of proinflammatory cytokines such as TNF-$\alpha$, IL-6, and IL-1$\beta$, and decrease myeloperoxidase (MPO) activity. In models of ulcerative colitis, it has been shown to protect intestinal barrier function by maintaining tight junction proteins like ZO-1 and occludin, while also modulating the gut microbiota (notably increasing *Akkermansiaceae*) and inhibiting apoptosis. It is recognized as a health functional food ingredient by the KFDA and holds FDA GRAS status, with research extending into osteoarthritis, muscle atrophy, and atopic dermatitis.

Brand names
Polycan
Other names
beta-1,3/1,6-glucanAureobasidium pullulans SM-2001 exopolymersextracellular polysaccharides from Aureobasidium pullulans SM-2001
02

Targets

αMβ2 (Integrin αMβ2)CLEC7A (Dectin-1)TLR (Toll-like receptors)

Beyond the preview

Go deeper on polycan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polycan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call